

**FILE COPY**  
**PATENT**

**Docket No.: 114232.107**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


In re of:

Leland SHAPIRO

Serial No. 09/518,098

Filed: March 3, 2000

For: **INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND  
COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS**



**Attn: Applications Branch**

Group Art Unit: 1646

**RECEIVED**  
NOV 07 2000  
TECH CENTER 1600/2900

**REQUEST FOR CORRECTED FILING RECEIPT**

Assistant Commissioner  
of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Attached is a copy of the incorrect Official Filing Receipt received from the U.S. Patent and Trademark Office in the above-referenced application.

The "Title" has the following errors:

please change "proteaseactivity" to --protease activity--  
as marked in red on the attached copy.

It is requested that a corrected filing receipt be issued.

Because the error is that of the U.S. Patent Office, it is believed that no fee is required with regard to this Request, however, in the event that a fee is required, the Commissioner is authorized to charge such fee to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

A handwritten signature in cursive script, appearing to read "Corinne M. Pouliquen".

Corinne M. Pouliquen  
Registration No. 35,753

600 Fourteenth Street  
Washington, D.C. 20005-2004  
Telephone: (202) 220-1200  
Facsimile: (202) 220-1201

Date: October 16, 2000


**FILING RECEIPT**

\*OC000000005343153\*

**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**Address: ASSISTANT SECRETARY AND  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/518,098	03/03/2000	1646	999	114232.107	14	45	14

21269  
PEPPER HAMILTON  
HAMILTON SQUARE  
600 FOURTEENTH STREET NW  
WASHINGTON, DC 20005



Date Mailed: 08/22/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Leland Shapiro, Denver, CO ;

**Continuing Data as Claimed by Applicant**

THIS APPLN CLAIMS BENEFIT OF 60/123,167 03/05/1999  
WHICH CLAIMS BENEFIT OF 60/137,795 06/03/1999

**Foreign Applications**

If Required, Foreign Filing License Granted 05/22/2000

**\*\* SMALL ENTITY \*\*****Title**

*protease activity*  
Inhibitors of serine ~~protease activity~~, methods and compositions for treatment of viral infections

**Preliminary Class**

514

Data entry by : HARRISON, BRUCE

Team : OIPE

Date: 08/22/2000



**RECEIVED**  
 NOV 07 2000  
 TECH CENTER 1600/2900

**LICENSE FOR FOREIGN FILING UNDER  
 Title 35, United States Code, Section 184  
 Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
 Office of Initial Patent Examination  
 Customer Service Center  
 Washington, DC 20231



UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**  
 MAY 07 2000  
 TECH CENTER 1600/2000
**FILE COPY**
 COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov


Bib Data Sheet

<b>SERIAL NUMBER</b> 09/518,098	<b>FILING DATE</b> 03/03/2000 <b>RULE</b> -	<b>CLASS</b> 514	<b>GROUP ART UNIT</b> 1646	<b>ATTORNEY DOCKET NO.</b> 114232.107
<b>APPLICANTS</b> Leland Shapiro, Denver, CO ;				
<b>** CONTINUING DATA *****</b> THIS APPLN CLAIMS BENEFIT OF 60/123,167 03/05/1999 WHICH CLAIMS BENEFIT OF 60/137,795 06/03/1999				
<b>** FOREIGN APPLICATIONS *****</b>				
<b>IF REQUIRED, FOREIGN FILING LICENSE</b> <b>GRANTED ** 05/22/2000</b>				
<b>** SMALL ENTITY **</b>				
Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met Allowance Verified and Acknowledged Examiner's Signature _____ Initials _____		<b>STATE OR COUNTRY</b> CO	<b>SHEETS DRAWING</b> 14	<b>TOTAL CLAIMS</b> 45
<b>INDEPENDENT CLAIMS</b> 14				
<b>ADDRESS</b> 21269				
<b>TITLE</b> Inhibitors of serine protease activity, methods and compositions for treatment of viral infections				
<b>FILING FEE RECEIVED</b> 999	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	